ResearcherTokyo Metropolitan Komagome HospitalActive in the last 2 years
Toru Aoyama
Matched on ORCID iD 0000-0003-3307-7656; OpenAlex author ID A5102753839. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 3, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 11
2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 2 papers · 2024: 3 papers · 2025: 1 paper
Papers 7
- Adjuvant Treatment for Resectable Pancreatic Cancer. Co-author DOI 10.21873/anticanres.17519↗
- Clinical usefulness of C-reactive protein-albumin-lymphocyte (CALLY) index as a prognostic biomarker in patients undergoing surgical resection of pancreatic ca… First author DOI 10.1007/s00423-024-03512-8↗
- Prognostic nutritional index is an independent risk factor for continuing S-1 adjuvant chemotherapy in patients with pancreatic cancer who received neoadjuvant… First author DOI 10.1186/s12885-024-13244-z↗
- Loss of Skeletal Muscle Mass During Neoadjuvant Chemotherapy for Pancreatic Cancer Is Related to the Continuation of S-1 Adjuvant Chemotherapy After Pancreatec… First author DOI 10.21873/anticanres.17286↗
- Incidence and Risk of Venous Thromboembolism in Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemotherapy. Co-author DOI 10.21873/anticanres.16327↗
- Clinical Impact of Nutrition and Inflammation Assessment Tools in Pancreatic Cancer Treatment. Co-author DOI 10.21873/anticanres.16572↗
- [A Case of Pancreatic Cancer Associated with Autoimmune Pancreatitis]. Co-author PMID 27760963↗
Closest collaborators
The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Masaaki Murakawa · 5 shared papers, 2016–2024 · strength 0.74
- Paper Clinical usefulness of C-reactive protein-albumin-lymphocyte (CALLY) index as a prognostic biomarker in patients underg… DOI 10.1007/s00423-024-03512-8↗
- Paper Prognostic nutritional index is an independent risk factor for continuing S-1 adjuvant chemotherapy in patients with pa… DOI 10.1186/s12885-024-13244-z↗
- Paper Loss of Skeletal Muscle Mass During Neoadjuvant Chemotherapy for Pancreatic Cancer Is Related to the Continuation of S-… DOI 10.21873/anticanres.17286↗
- Makoto Ueno · 5 shared papers, 2016–2024 · strength 0.74
- Paper Clinical usefulness of C-reactive protein-albumin-lymphocyte (CALLY) index as a prognostic biomarker in patients underg… DOI 10.1007/s00423-024-03512-8↗
- Paper Prognostic nutritional index is an independent risk factor for continuing S-1 adjuvant chemotherapy in patients with pa… DOI 10.1186/s12885-024-13244-z↗
- Paper Loss of Skeletal Muscle Mass During Neoadjuvant Chemotherapy for Pancreatic Cancer Is Related to the Continuation of S-… DOI 10.21873/anticanres.17286↗
- Soichiro Morinaga · 5 shared papers, 2016–2024 · strength 0.74
- Paper Clinical usefulness of C-reactive protein-albumin-lymphocyte (CALLY) index as a prognostic biomarker in patients underg… DOI 10.1007/s00423-024-03512-8↗
- Paper Prognostic nutritional index is an independent risk factor for continuing S-1 adjuvant chemotherapy in patients with pa… DOI 10.1186/s12885-024-13244-z↗
- Paper Loss of Skeletal Muscle Mass During Neoadjuvant Chemotherapy for Pancreatic Cancer Is Related to the Continuation of S-… DOI 10.21873/anticanres.17286↗
- Shinnosuke Kawahara · 4 shared papers, 2023–2024 · strength 0.69
- Paper Clinical usefulness of C-reactive protein-albumin-lymphocyte (CALLY) index as a prognostic biomarker in patients underg… DOI 10.1007/s00423-024-03512-8↗
- Paper Prognostic nutritional index is an independent risk factor for continuing S-1 adjuvant chemotherapy in patients with pa… DOI 10.1186/s12885-024-13244-z↗
- Paper Loss of Skeletal Muscle Mass During Neoadjuvant Chemotherapy for Pancreatic Cancer Is Related to the Continuation of S-… DOI 10.21873/anticanres.17286↗
- Naoto Yamamoto · 4 shared papers, 2023–2024 · strength 0.69
- Paper Clinical usefulness of C-reactive protein-albumin-lymphocyte (CALLY) index as a prognostic biomarker in patients underg… DOI 10.1007/s00423-024-03512-8↗
- Paper Prognostic nutritional index is an independent risk factor for continuing S-1 adjuvant chemotherapy in patients with pa… DOI 10.1186/s12885-024-13244-z↗
- Paper Loss of Skeletal Muscle Mass During Neoadjuvant Chemotherapy for Pancreatic Cancer Is Related to the Continuation of S-… DOI 10.21873/anticanres.17286↗
- Mariko Kamiya · 3 shared papers, 2023–2024 · strength 0.52
- Paper Clinical usefulness of C-reactive protein-albumin-lymphocyte (CALLY) index as a prognostic biomarker in patients underg… DOI 10.1007/s00423-024-03512-8↗
- Paper Loss of Skeletal Muscle Mass During Neoadjuvant Chemotherapy for Pancreatic Cancer Is Related to the Continuation of S-… DOI 10.21873/anticanres.17286↗
- Paper Incidence and Risk of Venous Thromboembolism in Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemot… DOI 10.21873/anticanres.16327↗
- Haruhiko Cho · 1 shared paper, 2025 · strength 0.37
- Yuto Kamioka · 2 shared papers, 2023–2024 · strength 0.34
- Paper Prognostic nutritional index is an independent risk factor for continuing S-1 adjuvant chemotherapy in patients with pa… DOI 10.1186/s12885-024-13244-z↗
- Paper Incidence and Risk of Venous Thromboembolism in Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemot… DOI 10.21873/anticanres.16327↗
- Takashi Oshima · 1 shared paper, 2023 · strength 0.24
- Kota Washimi · 1 shared paper, 2016 · strength 0.05
- Manabu Morimoto · 1 shared paper, 2016 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.